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Background: There are 0.9 catheterization labs per 100,000 inhabitants in Scotland for percutaneous 
coronary intervention (PCI) for acute myocardial infarction (AMI), which are much less accessible to patients 
in remote and rural areas. An uncommon but sinister sequalae following AMI is cardiogenic shock (CS) that 
could be refractory to inotropic support. CS complicates 5–15% of AMIs occurring in ST-segment elevation 
myocardial infarctions (STEMIs). Outcomes of CS are poor with mortalities of up to 90% reported in the 
literature in the absence of experienced care. We report our experience as the tertiary referral centre in 
Scotland for MCS and heart transplantation over 8 years.
Methods: A retrospective review of prospectively collected data was undertaken on all patients registered 
to the MCS service. The database was interrogated for patient demographics, type of mechanical circulatory 
support (MCS) and duration of MCS support, PCI-outcomes and survival to 30 days. A time-to-event 
analysis was performed using patient survival as the primary outcome measure. 
Results: Twenty-three patients (16 male, 7 females) were included. The median age of the patients as  
50 years (range, 45–56 years). VA-ECMO was the initial MCS of choice in 17 (73.9%) patients with BIVAD 
for 4 (17.4%) patients and LVAD for 2 (8.7%) patients. Thirty-day mortality was 21.8% in this cohort, 
however survival to discharge was 52.2%. Eleven (47.8%) patients recovered without the need for any 
further support, however only 9 (81.8%) patients in this subgroup survived to discharge. Three (13.0%) 
patients received a durable LVAD. In this subgroup, one patient was transplanted whereas two patients died 
due to complications while on support. The median length of in-hospital MCS support was 4 days. Median 
in-hospital stay was 27 days. Long-term follow up of up to 8 years demonstrates a high mortality beyond  
30 days up to the first 6 months post MCS support. 
Conclusions: MCS usage in these patients carries a high mortality in the early post-implantation period. 
However, there is a significant benefit to patients who survive the initial bridging period to recovery or 
destination therapy. 
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Introduction
In the preceding decades, Scotland has drastically reduced 
the mortality from coronary heart disease (72% reduction in 
2009 compared to 1950) (1). Despite this, post-MI mortality 
remains among the highest in Western Europe (1), branding 
Scotland as the ‘sick man of Europe’ (2). The inequalities in 
Scottish morbidity and mortality has resulted in an overall 
increase in health inequalities across the United Kingdom (3). 
Ischaemic heart disease is associated with a higher level of 
disability-adjusted life years (DALY) than any other condition 
in Scotland, mirroring not just the UK, but also DALY in the 
Global Burden of Disease Survey (4).
There are 0.9 catheterization labs per 100,000 inhabitants 
in Scotland for percutaneous coronary intervention (PCI) 
for acute myocardial infarction (AMI) (5), which are 
much less accessible to patients in remote and rural 
areas. An uncommon but sinister sequalae following 
AMI is cardiogenic shock (CS) that could be refractory 
to inotropic support. CS complicates 5–15% of AMIs 
occurring in ST-segment elevation myocardial infarctions 
(STEMIs) (6-8). Outcomes of CS are poor with mortalities 
of up to 90% reported in the literature in the absence of 
experienced care (9). 
Initial management of CS consists of identifying 
incidental complications e.g., acute left ventricular rupture 
or mitral regurgitation, assessing haemodynamics, and 
optimising the reperfusion in the culprit coronary artery. 
Clinical trials of therapeutic interventions have not led to 
changes in practice. The results of the Intra-Aortic Balloon 
Pump in Cardiogenic Shock II (IABP-SHOCK II) trial 
highlighted the lack of survival benefit from the routine use 
of IABP therapy for this condition (10). The only available 
option for patients with refractory, life-threatening illness 
would be the institution of mechanical circulatory support 
(MCS), involving either extracorporeal membranous 
oxygenation (ECMO) or ventricular assist devices 
(VADs). MCS can potentially improve survival, however, 
evidence is lacking. EURO-SHOCK (ID754946-2), 
which is a clinical trial funded by the EU-Horizons 2020 
7th Framework programme, will address this gap. EURO-
SHOCK is a multicentre, randomised, controlled trial of 
management involving ECMO vs. standard care without 
ECMO in patient with CS post-MI. Given the current gap 
in knowledge, we studied the outcomes following use of 
MCS for treatment of CS post-AMI in Scotland during an 
8-year period. 
Methods
Patients
All patients who were referred to the MCS service in the 
Golden Jubilee National Hospital from January 2009 to 
August 2017 following primary PCI-treated STEMI with 
refractory CS were included in this study. 
A retrospective review of prospectively collected data was 
undertaken on all patients registered to the MCS service. 
The database was interrogated for patient demographics, 
type of MCS [veno-arterial ECMO (VA-ECMO)/VAD] 
and duration of MCS support, PCI-outcomes and survival 
to 30 days. A time-to-event analysis was performed using 
patient survival as the primary outcome measure. Kaplan-
Meier curves were used to graphically display data of 30-day 
survival. Students t-tests and Mann-Whitney U tests were 
used to analyse data for 30-day survival for continuous data 
with Fisher’s exact test used for categorical data. The study 
was registered with the Clinical Governance and Audit 
Department at the Golden Jubilee National Hospital with a 
data protection registration number Z7996020. 
Results
Twenty-three patients (16 male, 7 females) were included. The 
median age of the patients as 50 years (range, 45–56 years). 
VA-ECMO was the initial MCS of choice in 17 (73.9%) 
patients with BIVAD for 4 (17.4%) patients and LVAD for 
2 (8.7%) patients. 30-day mortality was 21.8% in this 
cohort, however survival to discharge was 52.2%. 
Eleven (47.8%) patients recovered without the need for 
any further support, however only 9 (81.8%) patients in 
this subgroup survived to discharge. Three (13.0%) patients 
received a durable LVAD. In this subgroup, one patient was 
transplanted whereas two patients died due to complications 
while on support (VAD thrombus, disseminated intravascular 
coagulation). 
The median length of in-hospital MCS support was 
4 days (range, 4–43 days). Median in-hospital stay was 
27 days (range, 9–41 days).
The 30-day mortality data of survivors vs. non-survivors 
are as follows (Figure 1, Tables 1-4).
Removal of MCS
Death post-removal of MCS device were caused by 
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malignant arrhythmia (n=2).
Post 30-day survival
Three (13.0%) of patients underwent heart transplantation 
and are well at up to 6 years post-operatively. Patients who 
were successfully weaned had a mean ejection fraction of 
35.6%±10.2% and received ongoing heart failure medical 
therapy. 
Long-term follow up of up to 8 years is depicted in 
Figure 2. The curve demonstrates a high mortality beyond 
30-day up to the first 6-month post MCS support. 
Discussion
For the first time, we have documented MCS therapy and 
related outcomes in a contemporary Scottish population of 
patients with AMI complicated by CS. More than 79.2% 
of patients survived to 30 days. This result compares 
favourably to other studies investigating outcomes of 
patients receiving MCS therapy in AMI/CS. In the 
ENCOURAGE study, approximately half of the cohort 
survived to 30 days (11). One other North American 
study reported a 30-day mortality rate of 41% (12). 
Most other publications report a 30-day survival rate of 
23–76% survival rate in this specific patient cohort (13-15). 
Among the survivors, 16.7% subsequently underwent heart 
transplantation. 
There are challenges to comparisons of outcomes 
in post AMI-CS patients between studies, not least 
because of the heterogeneity in patient populations and 
practice. comparing outcomes of existing studies however 
is complicated by the variability of the cohorts as CS 
comprises a wide spectrum of clinical and haemodynamic 
instability. There is substantial heterogeneity with 
presentations of the patients with several factors being 
predictors of poor outcome in larger studies. A literature 
review revealed older age (6,16), signs of end-organ hypo-
perfusion (17), involvement of the LAD artery (16-18), 
severity of disease (triple vessel disease) (16) and renal 
failure (identified by elevated creatinine) (16,18). Our 
cohort was limited in size. Nonetheless, our findings 
indicate 30-day mortality results are similar to or potentially 
better than prior cohort studies. 
We concentrated on the presenting pathology (AMI with CS) 
and not the device (VAD vs. ECMO) as we felt most 
patients would receive a strategy that was either escalated 
or de-escalated based on recovery. Patients who were 
improving for example were stepped down from ECMO to 
a VAD (short term or long term). ECMO was the treatment Figure 1 Kaplan-Meier curve showing 30-day survival.
Analysis time (days)
Kaplan-Meier survival estimate
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Table 1 Preoperative demographics of survivors and non-survivors
Details Total (n=23) Survivors (n=18) Non-survivor (n=5) P
Age, years [IQR] 50 [11] 50 [9.3] 56 [16] 0.289
Male gender, % 65 72 60 0.599
BMI, kg/m2 28.2±3.3 28.7±2.7 27.2±4.1 0.337
Hypertension, % 13 (3/23) 6 (1/18) 60 (3/5) 0.021
Smoker, % 35 (8/23) 39 (7/18) 20 (1/5) 0.621
Diabetes mellitus, % 4 (1/23) 0 20 (1/5) 0.217
Blood group A, % 48 (11/23) 44 (8/18) 60 (3/5) 0.640
The first column shows the total cohort with survivors and non-survivors in the succeeding columns. Continuous variables are expressed 
as median (IQR) while categorical variables are depicted as percentages [numerator = total affected/denominator (sample size)].
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Table 2 PCI demographics of survivors’ vs. non-survivors 
Details Total (n=23) Survivors (n=18) Non-survivor (n=5) P
Post PCI MAP, mmHg 47.9±8.1 48.1±8.7 47.0±5.4 0.755
Creatinine, μmol/L 200.7±109.2 198.4±87.9 201±120 0.951
PCI-MCS initiation time, hours 7 [18.5] 8 [19.5] 4 [2] 0.370
CPR in Cath Lab, % (n) 48 (11/23) 39 (7/18) 80 (4/5) 0.155
IABP in Cath Lab, % (n) 91 (21/23) 94 (17/18) 80 (4/5) 0.395
Bilirubin, mg/dL 11.5 [11] 11 [11] 16 [10] 0.551
AST, μ/L 463 [457.5] 383 [396.5] 825 [1,298] 0.052
ALT μ/L 174 [234] 164 [201.5] 258 [487] 0.126
HsTnI, ng/L 18,057 [11,241] 18,057 [12,422] 20,211 [12,708] 0.559
Pulmonary oedema at presentation, % (n) 78 (18/23) 72 (13/18) 100 (5/5) 0.545
Culprit vessel, % (n)
Isolated LAD 39 (9/23) 39 (7/18) 40 (2/5) 0.999
Isolated RCA 26 (6/23) 33 (6/18) 0 0.272
Isolated LCx 4 (1/23) 0 (0/18) 20 (1/5) 0.217
Isolated LMS 9 (2/23) 11 (2/18) 0 0.999
>1 vessel involvement, % (n) 22 (5/23) 17 (3/18) 40 (2/5) 0.291
The first column shows the total cohort with survivors and non-survivors in the succeeding columns. Continuous variables are expressed 
as median [IQR] while categorical variables are depicted as percentages [numerator = total affected/denominator (sample size)]. PCI, 
percutaneous coronary intervention; MAP, mean arterial pressure; MCS, mechanical circulatory support; CPR, cardiopulmonary resuscita-
tion; IABP, intra-aortic balloon pump; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HsTnT, highly sensitive troponin T; 
LAD, left anterior descending artery; LCx, left circumflex artery; LMS, left main stem artery; RCA, right coronary artery. 
Table 3 Post-operative details of survivors vs. non-survivors
Details Total (n=23) Survivors (n=18) Non-survivor (n=5) P
ECMO, % 74 (17/23) 72 (13/18) 80 (4/5) 0.999
VAD, % 26 (6/23) 28 (5/18) 20 (1/5) 0.999
Post MCS lactate, mmol/L 6.64±3.64 6.07±3.22 8.60±5.03 0.339
PaO2/FiO2 0.402±0.135 0.394±0.133 0.444±0.169 0.675
Post MCS MAP, mmHg 64.83±6.76 64.44±7.59 66.20±3.90 0.494
Inotrope score 25.0±18.3 18.1±10.2 50.0±22.1 0.035
Platelet (×103 units), μ/L 211.4±81.2 216.9±87.1 176.2±61.6 0.267
CRRT post-MCS 48 (11/23) 61 (11/18) 0 (0/5) 0.037
Sequential organ failure assessment (SOFA) score 8.00±2.35 8.22±2.51 7.20±1.64 0.307
The first column shows the total cohort with survivors and non-survivors in the succeeding columns. Continuous variables are expressed 
as mean ± SD while categorical variables are depicted as percentages [numerator = total affected/denominator (sample size)]. MCS, 
mechanical circulatory support; PaO2/FiO2, arterial oxygen partial pressure to fractional inspired oxygen; VAD, ventricular assist devices; 
ECMO, either extracorporeal membranous oxygenation; MAP, mean arterial pressure.
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of choice in most patients as in the acute phase, almost all 
the patients presented with acute pulmonary oedema. 
Almost half (47.8%) of the patients had their support 
successfully weaned from ECMO and/or VAD without 
any further support device or transplantation. Myocardial 
recovery has been reported in previous publications (19-21). 
VA-ECMO is readily available and can be rapidly instituted 
percutaneously negating the need for operating theatre 
resources. Some limitations to ECMO have been reported 
in the literature. This includes inadequate left ventricular 
decompression as emptying depends on the native ejection 
function of the ventricle. Decreasing the flow rate on 
the ECMO circuit also reduces afterload alongside using 
inotropes such as dobutamine to improve contractility and 
decrease ejection. This may result in pulmonary hypertension, 
oedema and bleeding (22). The interaction between the 
tubing surfaces causes activation of monocytes and release 
of interleukins 1 and 6 (23). Some of the decompression 
can be attenuated by IABP insertion. It is associated with a 
smaller left ventricular dimension and a lower pulmonary 
artery pressure by restoring pulsatility and decreasing 
left ventricular afterload (24). IABP may also reduce the 
mean of cerebral blood flow during myocardial stunning, 
and increases the mean flow during cardiac recovery (25). 
Activation of clotting cascades is the predominant reason 
for bleeding complications. Frequent echocardiograms are 
done at our unit to ensure there is adequate decompression 
of the right and left ventricles. Another deleterious effect 
of VA ECMO is the neurological morbidity. Brain death 
has been reported in up to 21% in adults treated in ECMO 
centres. Up to 50% of patients have evidence of cerebral 
injury (25). In our cohort, 26.1% of patients had evidence of 
a cerebral injury. The same deleterious effects of ECMO are 
also noted in VADs (about 20%) (26). 
Myocardial ischaemia is commonly the preceding event 
in CS (9,27). It impairs myocardial contractility which in 
turn reduces stroke volume. An impeded cardiac index 
causes tissue hypoperfusion, which includes coronary 
hypoperfusion causing worsening myocardial ischaemia, 
resulting in a vicious cycle. Serum lactate, creatinine and 
AST are used as surrogates of organ hypoperfusion in 
our study. Initial compensatory vasoconstriction arises 
from catecholamine release to increase blood pressure but 
systemic inflammatory response syndrome (SIRS) mediated 
pathological release of vasodilatory agents results in a net 
reduction in cardiac index. This acts in conjunction with 
Table 4 Post-operative complications of survivors vs. non-survivors
Complications Total (n=23) Survivors (n=18) Non-survivor (n=5) P
Pump thrombus, % (n) 9 (2/23) 6 (1/18) 20 (1/5) 0.395
Bleeding, % (n) 13 (3/23) 11 (2/18) 20 (1/5) 0.539
ICH, % (n) 13 (3/23) 11 (2/18) 20 (1/5) 0.539
TIA/stroke, % (n) 13 (3/23) 17 (3/18) 0 (0/5) 0.999
Distal limb amputation, % (n) 9 (2/23) 11 (2/18) 0 (0/5) 0.999
Ischaemic colitis, % (n) 4 (1/23) 0 (0/18) 20 (1/5) 0.999
Malignant arrhythmia, % (n) 9 (2/23) 11 (2/18) 0 (0/5) 0.999
Aspiration pneumonia 4 (1/23) 0 (0/18) 20 (1/5) 0.250
The first column shows the total cohort with survivors and non-survivors in the succeeding columns. Variables are depicted as percent-
ages [numerator = total affected/denominator (sample size)].
Figure 2 Kaplan-Meier curve showing outcomes at up to 8 years 
follow-up.
Analysis time (years)
Kaplan-Meier survival estimate
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the reduction in left ventricular function as a result of 
myocardial stunning from the primary insult. There is a 
small window of reversibility afforded during myocardial 
stunning by reperfusion which is facilitated by early 
reperfusion (28). Capillary leakage from SIRS causes tissue 
oedema and a reduction in circulating volume. 
Decision making for MCS is also an important part of the 
discussion. Traditional ethical principles are not straightforward 
when applied to ECMO patients as it is often seen as the ceiling 
of therapy available. A survey of self-reported physicians with 
vast experience in VA-ECMO revealed majority of physicians 
felt physicians should have the right to discontinue management 
over family’s objection (29). MCS is a costly intervention 
thereby complicating the decision-making process with 
finite resources available for clinicians in the National 
Health Service (NHS). In our unit, a multidisciplinary team 
is consulted to ensure an informed decision which takes into 
account all facets of care prior to initiating MCS support. 
There are still some limitations in this study. The data 
presented represents the first reported series of patients in 
Scotland with AMI complicated by CS treated with MCS. 
However, as it is a retrospective study with a small cohort of 
patients, the reproducibility of the results may vary and may 
not capture the European or British population as a whole. 
There is a selection bias in the sample as only patients who 
were deemed potentially salvageable were included in the 
study, which may comparisons with other studies difficult. 
Conclusions
MCS usage in these patients carries a high mortality in 
the early post-implantation period. However, there is 
a significant benefit to patients who survive the initial 
bridging period to recovery or destination therapy. Further 
prospective studies are needed to identify predictors of 
long-term survival. 
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